The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Role of the Cdc25A phosphatase in human breast cancer
Open accessAbstract
The phosphatase Cdc25A plays an important role in cell cycle regulation by removing inhibitory phosphates from tyrosine and threonine residues of cyclin-dependent kinases, and it has been shown to transform diploid murine fibroblasts in cooperation with activated Ras. Here we show that Cdc25A is overexpressed in primary breast tumors and that such overexpression is correlated with higher levels of cyclin-dependent kinase 2 (Cdk2) enzymatic activity in vivo. Furthermore, in the breast cancer cell line MCF-7, Cdc25A activity is necessary for both the activation of Cdk2 and the subsequent induction of S-phase entry. Finally, in a series of small (< 1 cm) breast carcinomas, overexpression of Cdc25A was found in 47% of patients and was associated with poor survival. These data suggest that overexpression of Cdc25A contributes to the biological behavior of primary breast tumors and that both Cdc25A and Cdk2 are suitable therapeutic targets in early-stage breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Rapid Destruction of Human Cdc25A in Response to DNA Damage
Mailand, N., Falck, J., Lukas, C., Syljuåsen, R. G., Welcker, M., Bartek, J., & Lukas, J. (2000) · Science · doi:10.1126/science.288.5470.1425 · Cited by 787
Cited by
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
“, another proto-oncogene overexpressed in many carcinoma”
Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer
Frescas, D., & Pagano, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2396 · Cited by 890
Self-citationCDC25 phosphatases in cancer cells: key players? Good targets?
Boutros, R., Lobjois, V., & Ducommun, B. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2169 · Cited by 714
Mammalian G1- and S-phase checkpoints in response to DNA damage
Bartek, J., & Lukas, J. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00280-5 · Cited by 573
Sørensen, C. S., Syljuåsen, R. G., Falck, J., Schroeder, T., Rönnstrand, L., Khanna, K. K., Zhou, B.-B., Bartek, J., & Lukas, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00048-5 · Cited by 559
Pathways governing G1/S transition and their response to DNA damage
Bartek, J., & Lukas, J. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02114-7 · Cited by 471
Zhang, Z.-Y. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.083001.144616 · Cited by 433
Using expression profiling data to identify human microRNA targets
Huang, J. C., Babak, T., Corson, T. W., Chua, G., Khan, S., Gallie, B. L., Hughes, T. R., Blencowe, B. J., Frey, B. J., & Morris, Q. D. (2007) · Nature Methods · doi:10.1038/nmeth1130 · Cited by 394
Cell Cycle Activation Linked to Neuronal Cell Death Initiated by DNA Damage
Kruman, I. I., Wersto, R. P., Cardozo-Pelaez, F., Smilenov, L., Chan, S. L., Chrest, F. J., Emokpae, R., Gorospe, M., & Mattson, M. P. (2004) · Neuron · doi:10.1016/s0896-6273(04)00017-0 · Cited by 369
Ubiquitin signaling in cell cycle control and tumorigenesis
Dang, F., Nie, L., & Wei, W. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00648-0 · Cited by 348
Protein tyrosine phosphatases: prospects for therapeutics
Zhang, Z.-Y. (2001) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(00)00223-4 · Cited by 348
Lack of PTEN sequesters CHK1 and initiates genetic instability
Puc, J., Keniry, M., Li, H. S., Pandita, T. K., Choudhury, A. D., Memeo, L., Mansukhani, M., Murty, V. V. V. S., Gaciong, Z., Meek, S. E. M., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.009 · Cited by 328
Regulation of G2/M events by Cdc25A through phosphorylation‐dependent modulation of its stability
Mailand, N., Podtelejnikov, A. V., Groth, A., Mann, M., Bartek, J., & Lukas, J. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf567 · Cited by 315
Kristjánsdóttir, K., & Rudolph, J. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.07.007 · Cited by 313
p38 MAP Kinase's Emerging Role as a Tumor Suppressor
(2004) · Advances in Cancer Research · doi:10.1016/s0065-230x(04)92005-2 · Cited by 290
Alkylating agents and cancer therapy
Ralhan, R., & Kaur, J. (2007) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.17.9.1061 · Cited by 147
Nguyen, D. X., Westbrook, T. F., & McCance, D. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.2.619-632.2002 · Cited by 71
BRE/BRCC45 regulates CDC25A stability by recruiting USP7 in response to DNA damage.
Biswas, K., Philip, S., Yadav, A., Martin, B. K., Burkett, S., Singh, V., Babbar, A., North, S. L., Chang, S., & Sharan, S. K. (2018) · Nature Communications · doi:10.1038/s41467-018-03020-6 · Cited by 41
Metadata
- Authors
- Cangi, M. G., Cukor, B., Soung, P., Signoretti, S., Moreira, G., Ranashinge, M., Cady, B., Pagano, M., & Loda, M.
- Venue
- Journal of Clinical Investigation
- Published
- 2000-09-15
- Volume
- 106
- Issue
- 6
- Pages
- 753-761
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2154930300
- Cited by
- 207
- References
- 2
- FWCI
- 6.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.